My Personal Therapeutics (MPT) is the commercial application of a treatment selection strategy developed at the Center for Personalized Cancer Therapeutics (CPCT) at the Icahn School of Medicine at Mount Sinai. This strategy – the Personal Discovery Process (PDP) – comprises whole exome sequencing of tumor and non-tumor tissue, unbiased identification of potential tumorigenic mutations, incorporation of the multiple mutations into fruit flies to serve as patient avatars, and the conduct of massive (400K fruit fly) screening campaigns of all FDA-approved drugs to identify specific drug combinations for individual patients. Using robotics, we evaluate more than 1,200 FDA approved drugs including non-cancer drugs, to identify drug combinations that significantly improve mortality in the avatar population. We then present the drug combinations to a tumor board who make the best treatment recommendation for the patient. PDP is the most comprehensive drug screening service for individuals with cancer.